MedTrace Logo

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

NCT07685808 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2026-07-06

No results posted yet for this study

Summary

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes.

The study is looking at:

* What side effects the study drug might cause
* How much study drug is in the blood at different times
* How well the study drug works
* What effects the study drug may have on the body at different dosing schedules
* If the body makes antibodies to the study drug as this may cause the study drug to not work as well

Conditions

  • Overweight or Obesity

Interventions

DRUG

Olatorepatide

Administered per the protocol

DRUG

Placebo

Administered per the protocol

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-29
Primary Completion
2028-01-21
Completion
2028-01-21
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07685808 on ClinicalTrials.gov